Association of heart rate with heart failure outcomes and the effects of empagliflozin in patients with preserved ejection fraction - EMPEROR-Preserved trial

被引：0
|
作者：
Boehm, M. [1 ]
Anker, S. D. [2 ]
Mahfoud, F. [1 ]
Filippatos, G. [3 ]
Ferreira, J. P. [4 ]
Pocock, S. J. [5 ]
Brueckmann, M. [6 ]
Linetzky, B. [7 ]
Schueler, E. [8 ]
Wanner, C. [9 ]
Zannad, F. [4 ]
Packer, M. [10 ]
Butler, J. [11 ]
机构：
[1] Univ Hosp Saarland, Clin Internal Med Cardiol Angiol & Intens Care Me, Homburg, Germany
[2] Charite Univ Med Berlin, Dept Cardiol CVK, Berlin, Germany
[3] Natl & Kapodistrian Univ Athens, Athens Univ Hosp, Sch Med, Athens, Greece
[4] Univ Lorraine, Nancy, France
[5] London Sch Hyg & Trop Med, London, England
[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[7] Eli Lilly Interamer Inc, Buenos Aires, DF, Argentina
[8] mainanalyt GmbH, Sulzbach, Germany
[9] Wuerzburg Univ Clin, Wurzburg, Germany
[10] Baylor Univ Med Ctr, Dallas, TX USA
[11] Baylor Scott & White Hlth, Dallas, TX USA
来源：
EUROPEAN HEART JOURNAL | 2022年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：983 / 983
页数：1
相关论文
共 50 条
  • [21] Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
    Filippatos, Gerasimos
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 134 - 135
  • [22] Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Brueckmann, Martina
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zaremba-Pechmann, Liliana
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan
    JAMA CARDIOLOGY, 2023, 8 (07) : 640 - 649
  • [23] Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial"
    Gronda, Edoardo
    Colivicchi, Furio
    Zuccala, Giuseppe
    CIRCULATION, 2022, 145 (16) : E839 - E840
  • [24] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [25] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [26] Efficacy of Empagliflozin in Heart Failure with Preserved Ejection Fraction is related to the presence of echocardiographic features of diastolic dysfunction in the EMPEROR-Preserved trial.
    Coats, Andrew
    Butler, Javed
    Zimmet, Hendrik
    Anker, Stefan
    CIRCULATION, 2024, 150
  • [27] Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes
    Butler, Javed
    Filippatos, Gerasimos
    FUTURE CARDIOLOGY, 2023, 19 (15) : 723 - 733
  • [28] Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)
    Butler, J.
    Packer, M.
    Filippatos, G.
    Zannad, F.
    Salsali, A.
    Kimura, K.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J.
    Brueckmann, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 232 - 232
  • [29] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [30] Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved study
    Zannad, Faiez
    Macari, Steven
    FUTURE CARDIOLOGY, 2023, 19 (14) : 671 - 677
12345